In this regard, a clinical trial for targeting β1‐integrin as an anti‐cancer strategy was unsuccessful.[27, 28] However, since ITGB1 and ITGB4 executed distinct functions at different metastatic stages, a synergistic response might be observed following combined targeting of the two integrins. Here, ITGB1 is linked to cancer.